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A B S T R A C T
Purpose: To determine the efﬁcacy of the Modiﬁed Atkins Diet (MAD) and Ketogenic Diet (KD) in seizure
control within a population of myoclonic-astatic epilepsy (MAE) patients.
Methods: This was a retrospective, single center study evaluating the seizure control by high fat diets.
Seizure diaries kept by the parents performed seizure counts. All patients met the clinical criteria for
MAE.
Results: Nine patients met the clinical criteria. We found that both the MAD and KD were efﬁcacious in
complete seizure control and allowed other medications to be stopped in seven patients. Two patients
had greater than 90% seizure control without medications, one on the KD and the other on the MAD.
Seizure freedom has ranged from 13 to 36 months, and during this time four patients have been fully
weaned off of diet management. One patient was found to have a mutation in SLC2A1.
Conclusion: Our results suggest that strictly deﬁned MAE patients respond to the MAD with prolonged
seizure control. Some patients may require the KD for seizure freedom, suggesting a common pathway of
increased requirement for fats. Once controlled, those fully responsive to the Diet(s) could be weaned off
traditional seizure medications and in many, subsequently off the MAD or KD.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Doose syndrome is a primary generalized idiopathic seizure
disorder. Since the 1970s, the phenotype and nosology have
continued to evolve. Doose syndrome was originally noted to be a
generalized cryptogenic or sympathetic seizure disorder. However,
largely based on Doose’s original description, in 1989 and then in
2010, the International League Against Epilepsy (ILAE) deﬁned
Doose syndrome as myoclonic-astatic epilepsy (MAE) with (1)
normal development before the onset of seizures; (2) onset of
myoclonic, myoclonic-atonic, or atonic seizures between 7 months
and 6 years of age; (3) the presence of generalized spike or polyspike
wave EEG discharges; and (4) renamed MAE as myoclonic-atonic* Corresponding author at: Division of Pediatric Neurology Seattle Children’s
Hospital, Mailstop: MB 7.420, Seattle, WA 98105, USA.
Tel.: +1 206 987 2078; fax: +1 206 987 2649.
E-mail address: russ.saneto@seattlechildrens.org (R.P. Saneto).
http://dx.doi.org/10.1016/j.seizure.2014.10.009
1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reseizures.1,2 Initial EEGs are usually normal but with time show
bursts of irregular generalized 2–5 Hz spike/polyspike and wave
complexes. For continuity, we will use the term MAE for the article.
Historically, medical treatment of seizures in MAE has been
unsatisfactory, with seizure freedom only ranging from 0 to 36%.3,4
Recently, the Ketogenic Diet (KD) has been shown to have superior
efﬁcacy compared to traditional medical treatments.3–6 Limited
data suggests the Modiﬁed Atkins Diet (MAD) has efﬁcacy, but the
total number with MAE are limited and only two studies speciﬁc to
this condition using the MAD exists to our knowledge.7,8 However,
there is little data on long-term outcome using either diet. Here, we
describe our center’s data on MAD/KD in patients with MAE.
2. Methods
The Institutional Review Board at Seattle Children’s Hospital
approved this retrospective study. Nine patients met the criteria
for MAE and were on the MAD or KD (Table 1). All patients were
followed for at least 9 months following initiation of MAD or KD.served.
Table 1
Patient demographics seizures and EEG ﬁndings.
Patient Sex Age of ﬁrst seizure (months) Seizure types Febrile seizures onset (months) EEG
1 Male 26 A/GTC/M No GS-GPS/F
2 Male 22 A/GTC/M No GS
3 Male 35 A/GTC/M/AA/T No GS
4 Male 27 A/GTC No GS
5 Male 24 A/GTC/M/AA Yes (12) GS
6 Male 19 A/GTC/M Yes (18) GS
7 Male 29 A/GTC/AA/M No GS
8 Female 22 A/AA No GS
9 Male 40 A/GTC/AA/M No GS-GPS
Seizures: A, atonic seizure; GTC, Generalized tonic/clonic seizure; M, myoclonic seizure; AA, atypical absence seizure; T, tonic seizure. EEG: GS, generalized epileptiform
discharges; GPS, generalized polyspikes; F, focal discharges.
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the families and were reviewed at each clinic visit (Table 2).
Due to perceived compliance issues, several families elected to
start the MAD. Brieﬂy, the traditional KD (4:1 ratio) has only 2%
carbohydrate, 8% protein and 90% fat. The MAD (20 g of
carbohydrate per day) has 6% carbohydrate, 30% protein, and
64% fat. The MAD is less restrictive in food choices and hence more
adaptable to patient food tastes. The MAD used in our study
contained 10–20 g/day of carbohydrate.
All patients underwent magnetic resonance imaging (MRI).
Multiple EEG studies (n = 2–8) were performed in all patients at
our Institute and reviewed by one of the authors (RPS).
Genetic testing was performed using massive parallel sequenc-
ing of known epilepsy genes (Courtagen Life Sciences, Woborn,
MA). In 4/9 patients, genetic testing was not performed due to
insurance reasons or family preference.
3. Results
Nine patients were identiﬁed with the median age at onset at
2 years (Table 1). All patients had atonic seizures as well as other
seizure types (Table 1). Atonic seizures were clinically described as
head drops or brief loss of tone. Video-EEG studies were not
performed on all patients and seizure semiology was inferred by
parental description. All patients reported multiple daily or
monthly seizures prior to initiation of MAD or KD. By parental
report, all but Patient 3 had normal early development. Patient
3 had mild delay in expressive language, not gaining two-word
sentences until 2 years of age and more complex sentences until
3 years of age after which seizures began. MRI scans of the brain
were all considered to be normal. EEG studies demonstrated
generalized spike and wave discharges in all patients with a single
patient also having infrequent focal discharges (Table 1).Table 2
Seizure medication use before diet initiation and diet characteristics for seizure contro
Patient Seizure medications Diet 
Keto Diet ratio/MAD (m
1 LEV, LTG, VPA, RUF KD 4:1 (8)#
2 LEV MAD (2) > 4:1 (3)#
3 LEV, VPA, LTG, RUF, ZNS, CBZ MAD (4)#
4 LEV, TPM MAD (6)#
5 LEV, LTG, PB, OXC, VPA, RUF, TPM MAD (38) 
6 LEV, VPA, TPM KD 4:1 (12) 
7 LEV, LTG, VPA, KD 4:1 (6) 
8 LEV, LTG, VPA, ZNS MAD (8) 
9 LEV, LTG, VPA, ZNS MAD (45) 
Abbreviations: Seizure Medications: LEV, levetiracetam; LTG, lamotrigine; TPM, topirama
oxcarbazepine. Diet: KD, ketogenic diet; MAD, Modiﬁed Atkins Diet; Patient 2 was started
ketogenic diet. #Currently weaned off diet and off medications and no seizures report
myoclonic. Seizure frequency: * represents seizures per month; () represents limited seizu
having three GTC per month on ketogenic diet; ^Patient 7 patient was seizure free on th
seizure free but has since been lost to follow-up.Patient 8 was found to have a known pathological missense
mutation, c.376C > T (p.ARG126Cys) in the Helix 4 portion of
SCL2A1.
The age of diet initiation ranged from 19 to 61 months of age.
Seven of the nine patients became seizure free within several
weeks of dietary therapy, suggesting a very quick and complete
response to dietary management. In addition to the rapid response,
the MAD or KD induced a seizure freedom between 2 and 4 years
(Table 2).
Unfortunately, Patient 7 could not tolerate the long-term use of
the KD. The KD was stopped after several years due to compliance
and the patient had to be restarted on medications with ongoing
infrequent seizures. Patient 6 continued to have seizures on the KD
and parents stopped the diet and returned to medications. He is
currently having similar seizure frequency as compared to prior to
the KD.
Seven patients achieved continued seizure freedom on the MAD
or KD in the context of stopping all traditional seizure medications.
Patients 3 and 4 have been successfully weaned off the MAD and
have remained seizure free for 6–22 months. Patients 1 and 2 have
also been successfully weaned off the KD. Patient 2 required
increasing the fat ratio from the MAD to the KD to become seizure
free. He could still be successfully weaned off the diet and remain
seizure free. In Patients 1–4 a total of up to 36 months of seizure
freedom off the MAD or KD and all other seizure medications. In
those four patients still on the MAD, a total of 13–36 months of
seizure freedom have been obtained.
4. Discussion
MAE is a distinct electro-clinical syndrome.3 Treatment can be
problematic but some studies indicate that the KD can signiﬁcantly
reduce seizures; with up to 39% (33/85) becoming seizure free.4,8,9l.
Seizure types and frequency (per day)
onths to diet onset) Before diet After diet
2-GTC; 20-A; >25-M 0
3-GTC; 40-A 0
2-GTC; >15-A; >20-M 0
5-D; 3-GTC (lifetime) 0
>10-A; 4-D; 1-M* 1-M*
15-D: >25-M: <1-GTC 3-GTC*
7-D: 10-M: 50-A 0^
>8 A*: 5-D (lifetime) 0
35-M: 20-D: 3-GTC (lifetime) 0
te; VPA, valproic acid; RUF, ruﬁnamide; ZNS, zonisamide; CBZ, carbamazepine; OXC,
 on the Modiﬁed Atkins Diet but continued to have seizures and was switched to the
ed. Seizure types: GTC, generalized tonic clonic; A, atypical absence; D, drop; M,
re frequency; Patient 5 having one myoclonic seizure per month; Patient 5 currently
e ketogenic diet but did not tolerate diet and was placed on VPA and LTG and was
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International Ketogenic Diet Working Group identiﬁed MAE as one
of the epilepsy syndromes responsive to the KD.10 The use of the
MAD is less well documented. In a small group of patients, the MAD
decreased seizure frequency, but no patient became completely
seizure free.7–9,11
Our population of nine patients had a signiﬁcant response to
seizure reduction using the MAD or traditional KD (Table 2). All but
two patients became seizure free on the KD or MAD. Five patients
started on the MAD and one patient on the KD became completely
seizure free. At 12–15 months of seizure freedom, medications
were weaned off one-at-a time over an 8–10 week period. No
patient had break through seizures during the weaning period of
any of the medications.
EEGs were repeated in seven of the nine patients during seizure
freedom while on one of the Diets. Of those, ﬁve continued to show
interictal generalized epileptiform discharges and two had normal
studies. One of the patients with a normal EEG stopped the diet and
seizures returned (Patient 7) together with abnormal EEG ﬁndings
similar to before starting the KD. Response to treatment was
however, determined based on the clinical picture and not EEG
ﬁndings.
One patient initially started on the MAD with modest efﬁcacy
(>70% seizure reduction, data not shown), only became seizure
free when transitioned to the KD. This suggests that a ‘‘dose–
response’’ of increased fat ratio was required for seizure freedom,
as supported by the raised overnight fasting beta hydroxybutyrate
from an average of 4.5–5.5 mM on the MAD to 7.1–7.9 mM on the
KD. However, we do not know the exact beta hydroxybutyrate
level at the time of seizure events while on the MAD, nor can we
rule out that a more stable state of ketosis on the KD and not the
absolute ketosis was the etiology of better seizure control. Taken
together our data suggest that the Diets (KD/MAD) induce long-
term seizure freedom that is not dependent on traditional
medications. Overall, over 78% (7/9) became seizure free on one
of the diets. Dietary control of seizures also extended to the
removal of all traditional seizure medications, suggesting a
pathway(s) of seizure control elicited by the KD/MAD alone.
Two patients (Patients 6 and 7) raised several important points
about using the MAD and/or KD to control seizures. Patient
7 became seizure free on the KD, but was unable to tolerate the
long-term use of the diet. When switched to traditional seizure
medications, this patient began having break through seizures and,
unfortunately, was lost to follow-up. Would the less restrictive and
more tolerable MAD have been an option for seizure control in this
patient? Another question is the incomplete control of seizures in
some patients. Patients 1–5 and 9 became seizure free on the KD/
MAD without seizure medications. By contrast, Patient 6 did not
become seizure free and also had difﬁculty tolerating the KD. As
the diet has been weaned off, his seizure frequency has returned to
pre-KD numbers (data not shown). Within our MAE population,
there were MAD/KD non-responders as well as patients in whom
the beneﬁts of the diet did not remain after diet discontinuation.
Our data further validates distinct categories of MAE etiology
exist.8,12
Patient 8 had Glut 1 DS due to mutations in the SLC21A gene.
This patient did not have the usual ﬁndings associated with the
classical Glut 1 DS or reported extended phenotype recently
described with this syndrome, including the early-onset absence
seizures.13 This suggests that a population of patients with
generalized seizures can be identiﬁed with Glut 1 DS based on
complete control of seizures on dietary treatment, without
exhibiting the full features of Glut 1 DS.
Unfortunately, our data does not provide clues regarding which
MAE patients should be started on the MAD or KD. All patients
were proved to be early medically intractable due to failure of >2medications within 2 years of seizure onset, with the exception of
Patient 2.14 Neither the number of medications tried, nor the
seizure frequency or semiology was informative concerning diet
selection. Our data has a strong selection bias due to its
retrospective nature and due to the use of only patients who
met the clinical criteria of MAE and were placed on the KD or MAD.
The literature is clear that at other centers the MAD and KD were
not 100% successful.4,7–9,11 However, even given inherit problems
in our retrospective study, we think one strategy might be to
initiate the MAD and then transition those patients who do not
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